WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

R RESPIRATORY SYSTEM

Inhaled antiinfectives are classified in ATC group J - Antiinfectives for systemic use.


R01 NASAL PREPARATIONS

Varenicline nasal spray used for dry eye disease is classified in S01XA.


R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE

This group comprises preparations for local treatment in nasal congestion (e.g. sympathomimetics) or for prophylaxis and treatment of allergic rhinitis (e.g. corticosteroids, cromoglicate preparations). Most of the products are nasal drops, nasal sprays or nasal inhalants. Formulations approved for eye, ear and nose are classified in S03.
See also R01B - Nasal decongestants for systemic use, and
R06 - Antihistamines for systemic use.

The DDDs are based on treatment of both nostrils.

R01B NASAL DECONGESTANTS FOR SYSTEMIC USE

This group comprises preparations for systemic use in vasomotoric or allergic rhinitis etc., excl. plain antihistamines (see R06).
Combinations with antihistamines are classified in this group.


Cold preparations with therapeutic levels of analgesics/anti-inflammatory agents should be classified in the respective N02/M01 groups.

The DDDs are based on the treatment of rhinitis.

Last updated: 2024-01-26